Actinium Pharmaceuticals (Delaware) (ATNM) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Serina Therapeutics (SER) over the past year, losing 21.1% versus a loss of 71.9%. Over five years, ATNM leads with a -85.6% price change compared with -95.6% for SER. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($33.0 million vs $29.8 million), about 1.1 times the size.
Serina Therapeutics converts more of its revenue into profit, with a net margin of -14755.4% versus -37652.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | SER |
|---|---|---|
| Share price | $1.05 | $1.12 |
| Market cap | $33.01M | $29.76M |
| 1-day change | -1.87% | -6.67% |
| YTD return | -22.79% | -41.45% |
| 1-year return | -21.05% | -71.93% |
| 5-year return | -85.60% | -95.64% |
| P/E ratio (TTM) | 2.44 | — |
| EPS (TTM) | $0.43 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | $130.00K |
| Revenue growth (YoY) | — | +132.14% |
| Net income (latest FY) | $-33.89M | $-19.18M |
| Operating margin | -40274.44% | -18478.46% |
| Net margin | -37652.22% | -14755.38% |
| 52-week high | $1.72 | $4.26 |
| 52-week low | $0.735 | $1.06 |
| Distance from 52-week high | -38.95% | -73.71% |
| Analyst consensus | none | none |
| Avg. price target upside | +242.86% | +748.21% |
| Average volume | 193.83K | 68.98K |
| Shares outstanding | 31.44M | 26.57M |
| Employees | 27 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed SER by 50.9 percentage points over the past year.
- Serina Therapeutics is more profitable, keeping -14755.4 cents of every revenue dollar as net income versus -37652.2 cents for Actinium Pharmaceuticals (Delaware).
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
ATNM vs SER FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Serina Therapeutics?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $33.01M compared with $29.76M for Serina Therapeutics (SER).
Which stock has performed better over the past year, ATNM or SER?
ATNM returned -21.05% over the past 12 months, compared with -71.93% for SER (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.